Results 61 to 70 of about 3,401,781 (173)

Supplementary Figure S5 from Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S5. Overview of GO Biological process pathways found enriched in A. CD4+ T cells (6 hrs), B. CD8+ T cells (6 hrs), C. monocytes (6 hrs) and D. neutrophils (4 hrs) after treatment with 0.2 μg/mL CD20-TCB.</p>
Marina Bacac   +22 more
openaire   +1 more source

Supplementary Figure S10 from Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S10. Single cell RNA-sequencing of whole blood treated with 0.2 μg/mL CD20-TCB was performed using the BD Rhapsody platform</p>
Marina Bacac   +22 more
openaire   +1 more source

Supplementary Figure S2 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S2. Proportions of T cells, monocytes and neutrophils in human whole blood after treatment with 0.2 μg/mL CD20-TCB</p>
Marina Bacac   +22 more
openaire   +1 more source

A Retrospective Review of Tocilizumab for the Management of Blinatumomab (a Bispecific T Cell Engager)-Induced Cytokine Release Syndrome (CRS)

open access: yesBlood, 2018
Abstract Background: Treatment approaches for the management of CRS have been evolving, including the addition of the recently approved tocilizumab (Actemra®), an interleukin-6 receptor antagonist, for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening CRS. The authors report on the experience with
Jessica Choudhry   +2 more
openaire   +1 more source

Supplementary Figure S4 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S4. Multidimensional scaling plot of gene expression distances between pseudobulks</p>
Marina Bacac   +22 more
openaire   +1 more source

Supplementary Figure S3 from Dissecting the mechanisms underlying the Cytokine Release Syndrome (CRS) mediated by T Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S3. Identification of an interacting B and T cells cluster by scRNA sequencing of human whole blood treated with 0.2 μg/mL CD20-TCB using the BD Rhapsody platform.</p>
Marina Bacac   +22 more
openaire   +1 more source

Cytokine release syndrome

open access: yesJournal of Pediatric Critical Care
Cytokine release syndrome (CRS) is a severe, potentially life-threatening immune-mediated condition characterized by excessive cytokine secretion leading to systemic inflammation and multiorgan dysfunction.
Rachit Mehta, Indira Jayakumar
doaj   +1 more source

Supplementary Figure S12 from Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies

open access: yes, 2023
<p>Supplementary Figure S12. Individual tumor growth curves for each treatment group. OCI-Ly18 (DLBCL)-bearing humanized NSG mice were pre-treated with 30 mg/kg Gazyva (Gpt, grey arrow) and treated weekly with escalating doses of CD20-TCB (0.5 mg/kg, 1 mg/kg, 2 mg/kg, red arrows).
Marina Bacac   +22 more
openaire   +1 more source

Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma

open access: yesNature Communications
Cytokine release syndrome (CRS) is the most common complication of chimeric antigen receptor redirected T cells (CAR-T) therapy. CAR-T toxicity management has been greatly improved, but CRS remains a prime safety concern.
Shuangshuang Yang   +12 more
doaj   +1 more source

Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy

open access: yesBiomarker Research, 2018
Severe cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T cell (CAR-T) therapy can be life-threatening in some cases, and management of those toxicities is still a great challenge for physicians.
Zhenguang Wang, Weidong Han
doaj   +1 more source

Home - About - Disclaimer - Privacy